Open an account

Capricor Therapeutics

CAPR · NASDAQ

$6.61−$0.04 (−0.60%)TodayMarket closed ·
Prev close $6.65

About CAPR

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. The company is headquartered in San Diego, California and currently employs 231 full-time employees. The company went IPO on 2002-06-04. The firm's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.

Employees
231
Headquarters
San Diego, California
Listed
Jun 4, 2002
Sector
Health Care
Industry
Biotechnology
Website
capricor.com

CAPR key statistics

Market cap
384.30M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
3.63M
Volume
2.05M
Open price
$6.53
High today
$6.83
Low today
$6.47
52 Week high
$40.37
52 Week low
$2.96

Capricor Therapeutics (CAPR) at a glance

As of Oct 20, 2026, Capricor Therapeutics (CAPR) shares are priced at $6.61, giving the company a market cap of 384.30M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $6.47 and $6.83. The current price is 2.2% above the day's low and 3.3% below its high.

Volume so far is 2.05M shares, below the average of 3.63M shares a day.

Over the past year Capricor Therapeutics has ranged from $2.96 to $40.37, and now sits 10% of the way up that range.

Capricor Therapeutics met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$0.70 per share against an estimate of -$0.6018.

The average analyst price target is $24.14, 265.2% above the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

75%of 8 analyst ratings say Buy
  • Buy75.0%
  • Hold25.0%
  • Sell0.0%
Price target · 8 analystsAvg $24.14
Low
$7.07
Now
$6.61
High
$56.70

CAPR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 21.9% on average.

  1. Q3 FY24: reported -$0.38 per share against an estimate of -$0.3655
  2. Q4 FY24: reported -$0.16 per share against an estimate of -$0.2686
  3. Q1 FY25: reported -$0.53 per share against an estimate of -$0.323
  4. Q2 FY25: reported -$0.57 per share against an estimate of -$0.4783
  5. Q3 FY25: reported -$0.54 per share against an estimate of -$0.5585
  6. Q4 FY25: reported -$0.62 per share against an estimate of -$0.5508
  7. Q1 FY26: reported -$0.59 per share against an estimate of -$0.5421
  8. Q2 FY26: reported -$0.70 per share against an estimate of -$0.6018

CAPR news

  • Vandana Singh

    What's Going On With Capricor Therapeutics Stock Monday?

  • Henry Khederian

    Capricor Therapeutics Stock Surges: What's Going On?

  • Avi Kapoor

    Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday

  • Press releaseBusiness Wire

    CAPR CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026

  • Press releaseGlobe Newswire

    CAPR Investor Lawsuit: Capricor Therapeutics Sued for Securities Fraud on behalf of Investors with Losses – Contact BFA Law by September 28 Court Deadline

  • Press releaseGlobe Newswire

    CAPR 2-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline

  • Press releaseGlobe Newswire

    CAPR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026

  • Press releaseGlobe Newswire

    CAPRICOR DEADLINE SEPTEMBER 28th: Bragar Eagel & Squire, P.C. Urges Capricor Therapeutics, Inc. Investors With Large Losses to Contact the Firm Before the September 28th Deadline

Similar companies

Companies in the same industry as Capricor Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.